Hydrogen Sulfide

Hydrogen Sulfide

SCHEMBL3347200

S.S.c1ccc(SSc2ccccn2)nc1.c1ccc(SSc2ccccn2)nc1.c1ccc(SSc2ccccn2)nc1.c1ccc(SSc2ccccn2)nc1

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.94
EHMT1 Q9H9B1 1/20 0.94
APOBEC3G Q9HC16 1/20 0.94
L3MBTL1 Q9Y468 3/20 0.48
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46
P4HTM Q9NXG6 1/20 0.46
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27972393 0.97 EHMT2 (1.00) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
SCHEMBL21174 0.97 EHMT2 (1.00) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
SCHEMBL29349787 0.97 EHMT2 (1.00) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Hydrochloric Acid SCHEMBL10707236 0.94 EHMT2 (0.94) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Hydrochloric Acid SCHEMBL11726971 0.94 EHMT2 (0.94) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Ammonia Solution, Strong SCHEMBL421495 0.94 EHMT2 (0.94) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Hydrochloric Acid SCHEMBL8671988 0.94 EHMT2 (0.94) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Methyl Alcohol SCHEMBL28484914 0.92 EHMT2 (0.90) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
Ethylene SCHEMBL19138148 0.92 EHMT2 (0.90) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E
SCHEMBL11825400 0.87 EHMT2 (0.81) EHMT2EHMT1APOBEC3GL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120135092-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE 2012-05-31 US disclosed
US-20100292135-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-11-18 US disclosed
WO-2009154828-A9 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-05-06 WO disclosed
WO-2009154828-A2 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2009-12-23 WO disclosed
EP-1874801-A4 INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS UNIV NORTH CAROLINA (US) 2009-03-25 EP disclosed
EP-1874801-A2 INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS The University of North Carolina at Chapel Hill (US) 2008-01-09 EP disclosed
WO-2006096757-A2 INHIBITORS OF RECA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2006-09-14 WO disclosed
US-20060199768-A1 Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2006-09-07 US disclosed
EP-1067922-A1 AGENTS AND METHODS FOR MODULATION OF ZINC TRANSFER BY METALLOTHIONEIN THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 2001-01-17 EP disclosed
WO-1999049860-A1 AGENTS AND METHODS FOR MODULATION OF ZINC TRANSFER BY METALLOTHIONEIN THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199768-A1 Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens RECQL, DNA2, WRN EHMT2 3839/4885EHMT1 3580/4885APOBEC3G 1146/4885
US-20100292135-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS RECQL, DNA2, WRN EHMT2 3839/4885EHMT1 3580/4885APOBEC3G 1146/4885
US-20120135092-A1 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS RECQL, WRN, ADAR EHMT2 2889/4885EHMT1 2497/4885APOBEC3G 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.